Intestinal organoids for Cystic Fibrosis research

Significant progress has been made in the development of CFTR modulator therapy; however, current CFTR modulator therapies are only available for a minority of the CF-patient population. Additionally, heterogeneity in in vivo modulator response has been reported among individuals carrying homozygous F508del-CFTR, adding to the desire for an optimal prediction of response-to-therapy on an individual level. In the last decade, a lot of progress has been made in the development of primary cell cultures into 3D patient-derived disease models.

Source: Journal of Cystic Fibrosis - November 27, 2019 Category: Respiratory Medicine Authors: E. de Poel, J.W. Lefferts, J.M. Beekman Tags: Review Source Type: research